Cargando…

Cold Exposure and Oral Delivery of GLP-1R Agonists by an Engineered Probiotic Yeast Strain Have Antiobesity Effects in Mice

[Image: see text] Advanced microbiome therapeutics (AMTs) holds promise in utilizing engineered microbes such as bacteria or yeasts for innovative therapeutic applications, including the in situ delivery of therapeutic peptides. Glucagon-like peptide-1 receptor agonists, such as Exendin-4, have emer...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hedin, Karl Alex, Zhang, Hongbin, Kruse, Vibeke, Rees, Vanessa Emily, Bäckhed, Fredrik, Greiner, Thomas U., Vazquez-Uribe, Ruben, Sommer, Morten Otto Alexander
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Chemical Society 2023
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661039/ https://www.ncbi.nlm.nih.gov/pubmed/37827516 http://dx.doi.org/10.1021/acssynbio.3c00455

Ejemplares similares

Effects of broad-spectrum antibiotics on the colonisation of probiotic yeast Saccharomyces boulardii in the murine gastrointestinal tract
por: Hedin, Karl Alex, et al.
Publicado: (2022)

Biocontainment strategies for in vivo applications of Saccharomyces boulardii
por: Hedin, Karl Alex, et al.
Publicado: (2023)

Microbial regulation of GLP-1 and L-cell biology
por: Greiner, Thomas U., et al.
Publicado: (2016)

A Review on Role of Microbiome in Obesity and Antiobesity Properties of Probiotic Supplements
por: Sivamaruthi, Bhagavathi Sundaram, et al.
Publicado: (2019)

The Antiobesity Effect of GLP-1 Receptor Agonists Alone or in Combination with Metformin in Overweight /Obese Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis
por: Lyu, Xiaorui, et al.
Publicado: (2021)

Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
por: Madsen, Mette Simone Aae, et al.
Publicado: (2019)

Expression of Concern on “A Review on Role of Microbiome in Obesity and Antiobesity Properties of Probiotic Supplements”
por: International, BioMed Research
Publicado: (2022)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

Clinical Trial Highlights – GLP-1 agonists
por: McFarthing, Kevin, et al.
Publicado: (2020)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Obstetrician-Gynecologists' Strategies for Patient Initiation and Maintenance of Antiobesity Treatment with Glucagon-Like Peptide-1 Receptor Agonists
por: Gill, Lisa, et al.
Publicado: (2021)

Plants' Metabolites as Potential Antiobesity Agents
por: Gooda Sahib, Najla, et al.
Publicado: (2012)

Lorcaserin: A novel antiobesity drug
por: Brashier, Dick B. S., et al.
Publicado: (2014)

Current Understanding of Antiobesity Property of Capsaicin
por: Narang, Nithida, et al.
Publicado: (2017)

Copper Ionophores as Novel Antiobesity Therapeutics
por: Meggyesy, Peter M., et al.
Publicado: (2020)

A Synergistic Antiobesity Effect by a Combination of Capsinoids and Cold Temperature Through Promoting Beige Adipocyte Biogenesis
por: Ohyama, Kana, et al.
Publicado: (2016)

Novel GLP-1 Fusion Chimera as Potent Long Acting GLP-1 Receptor Agonist
por: Wang, Qinghua, et al.
Publicado: (2010)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Updates on Antiobesity Effect of Garcinia Origin (−)-HCA
por: Chuah, Li Oon, et al.
Publicado: (2013)

A Drosophila Model for Screening Antiobesity Agents
por: Men, Tran Thanh, et al.
Publicado: (2016)

Antiobesity Effects of Anthocyanins in Preclinical and Clinical Studies
por: Azzini, Elena, et al.
Publicado: (2017)

The Societal Value of Broader Access to Antiobesity Medications
por: Kabiri, Mina, et al.
Publicado: (2019)

Brain GLP‐1 and the regulation of food intake: GLP‐1 action in the brain and its implications for GLP‐1 receptor agonists in obesity treatment
por: Trapp, Stefan, et al.
Publicado: (2021)

The dual amylin and calcitonin receptor agonist KBP-089 and the GLP-1 receptor agonist liraglutide act complimentarily on body weight reduction and metabolic profile
por: Larsen, Anna Thorsø, et al.
Publicado: (2021)

Glucagon‐like peptide‐1 (GLP‐1) receptor agonists and their cardiovascular benefits—The role of the GLP‐1 receptor
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Special Report: Potential Strategies for Addressing GLP-1 and Dual GLP-1/GIP Receptor Agonist Shortages
por: Whitley, Heather P., et al.
Publicado: (2023)

GLP-1 Receptor Agonist Effects on Normal and Neoplastic Pancreata
por: Goggins, Michael
Publicado: (2012)

Role and development of GLP-1 receptor agonists in the management of diabetes
por: Chia, Chee W, et al.
Publicado: (2009)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff, Lisa M, et al.
Publicado: (2010)

Targeting GLP-1 receptor trafficking to improve agonist efficacy
por: Jones, Ben, et al.
Publicado: (2018)

GLP-1 receptor agonist ameliorates experimental lung fibrosis
por: Fandiño, Juan, et al.
Publicado: (2020)

An overview of GLP-1 agonists and recent cardiovascular outcomes trials
por: Sheahan, Kelsey H, et al.
Publicado: (2020)

Medullary Carcinoma of Thyroid Due to GLP-1 Receptor Agonist
por: Vemula, Hasitha, et al.
Publicado: (2021)

GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight
por: Monti, Giulia, et al.
Publicado: (2022)

GLP-1 receptor agonist as a modulator of innate immunity
por: Chen, Jun, et al.
Publicado: (2022)

Effects of GLP-1 receptor agonists on neurological complications of diabetes
por: García-Casares, Natalia, et al.
Publicado: (2023)

Characterization of Eight Bacterial Biosensors for Microbial Diagnostic and Therapeutic Applications
por: Vaaben, Troels Holger, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ujgue9d0ga7jk6a1jlnakocn6u